Algeta Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 175

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $2.7B

Algeta General Information

Description

Developer of novel targeted therapies for patients with cancer, based on its alpha-pharmaceutical platform. The company is focused to extend and improve cancer patient's lives by developing targeted therapies to fulfill unmet medical needs. It's lead product Alpharadin is used for treatment for cancer patients with bone metastases. They are also developing thorium targeted conjugates which are based on conjugating the alpha-emitter thorium-227 to tumor-targeting molecules.

Contact Information

Website
www.algeta.com
Formerly Known As
Anticancer Therapeutic Inventions
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Kaiser-Wilhelm-Allee 1
  • 51368 Leverkusen
  • Norway
+47 23
Primary Industry
Drug Discovery
Acquirer
Vertical(s)
Corporate Office
  • Kaiser-Wilhelm-Allee 1
  • 51368 Leverkusen
  • Norway
+47 23

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Algeta Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 06-Mar-2014 $2.7B Completed Generating Revenue
6. PIPE 15-Feb-2012 Completed Generating Revenue
5. Secondary Transaction - Open Market 07-Jul-2011 Completed Generating Revenue
4. PIPE 18-Feb-2009 Completed Generating Revenue
3. IPO 26-Mar-2007 Completed Generating Revenue
2. Later Stage VC (Series A) 01-Sep-2005 $29M $29M Completed Generating Revenue
1. Early Stage VC 01-Jan-2002 Completed Startup
To view Algeta’s complete valuation and funding history, request access »

Algeta Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Algeta Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Abingworth Venture Capital Minority
Advent Life Sciences Venture Capital Minority
Advent Venture Partners Venture Capital Minority
Birk Venture Venture Capital Minority
HealthCap Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Algeta FAQs

  • When was Algeta founded?

    Algeta was founded in 1997.

  • Where is Algeta headquartered?

    Algeta is headquartered in Leverkusen, Norway.

  • What is the size of Algeta?

    Algeta has 175 total employees.

  • What industry is Algeta in?

    Algeta’s primary industry is Drug Discovery.

  • Is Algeta a private or public company?

    Algeta is a Private company.

  • What is the current valuation of Algeta?

    The current valuation of Algeta is .

  • What is Algeta’s current revenue?

    The current revenue for Algeta is .

  • How much funding has Algeta raised over time?

    Algeta has raised $154M.

  • Who are Algeta’s investors?

    Abingworth, Advent Life Sciences, Advent Venture Partners, Birk Venture, and HealthCap are 5 of 9 investors who have invested in Algeta.

  • When was Algeta acquired?

    Algeta was acquired on 06-Mar-2014.

  • Who acquired Algeta?

    Algeta was acquired by Bayer.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process